REGENXBIO's three-year durability data for surabgene lomparvovec in diabetic retinopathy signals a potential shift toward one-time gene therapy in a market dominated by repeated injections
Executive summary: REGENXBIO presented three-year durability data for its gene therapy surabgene lomparvovec in diabetic retinopathy at the Retina Society Annual Scientific Meeting, showing that a majority of Dose Level 3 participants achieved >2-step DRSS improvement with no vision-threatening events or additional treatment. If confirmed, a one-time gene therapy could replace chronic anti-VEGF injections for diabetic retinopathy, a large and growing market, potentially reducing healthcare costs and improving patient compliance.
Who is involved: REGENXBIO, the Retina Society, patients with non-proliferative diabetic retinopathy, and potentially regulatory bodies like the FDA.
Likely next: REGENXBIO is likely to use these data to support regulatory submissions and advance the program into later-stage trials, possibly seeking breakthrough therapy designation.
REGENXBIO presented three-year follow-up data from its surabgene lomparvovec program in diabetic retinopathy at the Retina Society Annual Scientific Meeting. The majority of Dose Level 3 participants with non-proliferative diabetic retinopathy achieved a >2-step improvement on the Diabetic Retinopathy Severity Scale, with no vision-threatening events and no additional treatment required. No intraocular inflammation was observed with a short-course steroid regimen. These results, if confirmed, could position sura-vec as a durable alternative to chronic anti-VEGF injections, potentially reducing the treatment burden for a large patient population. The data also provide a foundation for regulatory discussions and further clinical development.
What's next — scenarios
Base: Regulatory advancement and continued development (60%)
REGENXBIO progresses sura-vec into pivotal trials, with potential FDA meetings within 12 months.
- Publication of full data in a peer-reviewed journal
- Announcement of phase 3 trial initiation
Upside: Accelerated approval or partnership (25%)
REGENXBIO secures a major partnership or breakthrough therapy designation, accelerating market entry and boosting stock value.
- FDA grants breakthrough therapy designation
- A major pharma announces collaboration
Downside: Safety or efficacy concerns in larger trials (15%)
Longer-term follow-up reveals safety issues or loss of efficacy, delaying development and impacting REGENXBIO's pipeline.
- Unexpected adverse events reported in extended follow-up
- Failure to replicate results in a larger cohort
Timeline
- — REGENXBIO Presents Positive Three-Year Durability Data for Surabgene Lomparvovec in Diabetic Retinopathy at Retina Society Annual Scientific Meeting (PR Newswire)
- — Lancet Neurology Study Using Alamar Biosciences’ Technology Reveals Divergent Biological Responses to Alzheimer’s Treatment (GlobeNewswire)
Analysis — what this means
Sectors affected
- Ophthalmology gene therapy
- Diabetic retinopathy treatment
- Anti-VEGF injection market (e.g., Eylea, Lucentis)
Regulatory implications
- Potential FDA review of gene therapy for diabetic retinopathy, with possible breakthrough therapy designation.
Historical parallels
- Luxturna (voretigene neparvovec) for inherited retinal disease, approved by FDA in 2017, demonstrated durable response.
- Zolgensma for spinal muscular atrophy, approved in 2019, showing durability of one-time gene therapy.
Sources
- REGENXBIO Presents Positive Three-Year Durability Data for Surabgene Lomparvovec in Diabetic Retinopathy at Retina Society Annual Scientific Meeting — PR Newswire
- Lancet Neurology Study Using Alamar Biosciences’ Technology Reveals Divergent Biological Responses to Alzheimer’s Treatment — GlobeNewswire